PSYREFLECT

Issue #66

August 20, 2026

#1Research

Where the Lesion Sits Adds a Little – and Only at the Dementia End

The lesion map earns its keep at the dementia end of the spectrum and goes quiet exactly where an early marker would be worth having.

white matter hyperintensitiesvascular cognitive impairmentdementianeuroimaging
5 minRead analysis
#2Research

Latrepirdine comes back: 3.36 ADAS-cog points on top of memantine, and nothing else moves

A cognitive score moved by three and a half points while daily function only held level and no change in quality of life was reported, and that gap is not a pharmacological problem.

alzheimer's diseasedementialatrepirdineclinical trial
9 minRead analysis
#3Tool

Six sessions, a manual and a psychology graduate: what DREAMS START can and cannot show

This trial has no objective sleep outcome at all: the registered actigraphy was usable in 22.3% of dyads at 8 months, and every reported number came from the unmasked family carer.

dementiasleepcaregiversnon-pharmacological intervention
8 minRead analysis
#4Industry

Eight per cent eligible: a US model prices the anti-amyloid pathway against dementia care

Eligibility, not effect size, decides the national arithmetic: 1.03 million people can receive the drug, 6.16 million can receive the care.

dementiaAlzheimer's diseasehealth economicsanti-amyloid therapy
7 minRead analysis
#5Industry

After the dementia diagnosis, the prescription outlasts the guidance

The first antipsychotic course in dementia runs to a model-adjusted median of seven months in a system whose guidance is written in weeks.

dementiaantipsychoticsprescribingdeprescribing
7 minRead analysis
#6Resource

WHO iSupport: a free 23-lesson carer manual, four PDFs on one IRIS record, and one null trial

The manual is a content base, not a stand-alone intervention: the largest iSupport trial to date found no separation from usual care when carers were left to work through it alone.

dementiacarersWHOopen access
7 minRead analysis